Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TMPRSS2 | O15393 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.45 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.45 |
| ▸ | POLRMT | O00411 | 1/20 | 0.41 |
| ▸ | P2RY1 | P47900 | 2/20 | 0.39 |
| ▸ | ENPP1 | P22413 | 4/20 | 0.37 |
| ▸ | P2RY11 | Q96G91 | 1/20 | 0.37 |
| ▸ | ENTPD2 | Q9Y5L3 | 1/20 | 0.37 |
| ▸ | PLCG1 | P19174 | 1/20 | 0.37 |
| ▸ | NT5E | P21589 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17719380 | 0.93 | ALDH1A1 (0.43) | TMPRSS2ALDH1A1P2RX1P2RX3POLRMT | |
| SCHEMBL17719238 | 0.93 | POLRMT (0.48) | TMPRSS2P2RX1P2RX3POLRMT | |
| SCHEMBL17719379 | 0.92 | ALDH1A1 (0.45) | TMPRSS2ALDH1A1P2RX1P2RX3POLRMT | |
| Rdv-Tp SCHEMBL26003192 | 0.91 | POLRMT (0.51) | TMPRSS2P2RX1P2RX3POLRMTP2RY1 | |
| Rdv-Tp SCHEMBL24492746 | 0.91 | POLRMT (0.51) | TMPRSS2P2RX1P2RX3POLRMTP2RY1 | |
| Rdv-Tp SCHEMBL23278555 | 0.91 | POLRMT (0.51) | TMPRSS2P2RX1P2RX3POLRMTP2RY1 | |
| Rdv-Tp SCHEMBL10120881 | 0.91 | POLRMT (0.51) | TMPRSS2P2RX1P2RX3POLRMTP2RY1 | |
| Rdv-Tp SCHEMBL24492745 | 0.91 | POLRMT (0.51) | TMPRSS2P2RX1P2RX3POLRMTP2RY1 | |
| SCHEMBL17719237 | 0.89 | TMPRSS2 (0.50) | TMPRSS2POLRMTP2RY1P2RY11 | |
| SCHEMBL24917304 | 0.88 | TMPRSS2 (0.47) | TMPRSS2ALDH1A1P2RX1P2RX3POLRMT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11344565-B2 | Methods for the preparation of ribosides | GILEAD SCIENCES, INC. (US) | 2022-05-31 | — | — | US | disclosed |
| US-20160122356-A1 | METHODS FOR THE PREPARATION OF RIBOSIDES | GILEAD SCIENCES, INC. | 2016-05-05 | — | — | US | disclosed |
| US-20160122356-A1 | METHODS FOR THE PREPARATION OF RIBOSIDES | GILEAD SCIENCES, INC. | 2016-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160122356-A1 | METHODS FOR THE PREPARATION OF RIBOSIDES | PRPS1, PRPF4, PRPF31 | TMPRSS2 3100/4885ALDH1A1 1567/4885P2RX1 1465/4885 |
| US-11344565-B2 | Methods for the preparation of ribosides | RUVBL2, RUVBL1, EIF2AK2 | TMPRSS2 3973/4885ALDH1A1 4115/4885P2RX1 2174/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.